Category: BLOG

(Wired) – As nights get hotter around the globe due to climate change, the prevalence of sleep apnea is expected to increase by as much as threefold.

One particularly eye-opening study, carried out by giving under-mattress sleep sensors to 67,558 people across 17 European countries and recording their sleep data over the course of five summers, found that the prevalence of sleep apnea events increased by 13 percent at the peak of a heatwave. It also revealed that for every 1 degree Celsius increase in the nighttime temperature, the rates of sleep apnea events rose by 1.1 percent, with the risk being even greater during especially humid nights. (Read More)

(New York Times) – Researchers believe increasing use of cannabis may be contributing to a rise in new cases of schizophrenia and related disorders at younger ages.

A new analysis of birth cohorts in the Canadian province of Ontario has found a striking rise in the incidence of psychotic disorders among young people, a finding that its authors said could reflect teens’ increasing use of substances like cannabis, stimulants and hallucinogens.

The study, published on Monday in The Canadian Medical Association Journal, found that the rate of new diagnoses of psychotic disorders among people ages 14 to 20 increased by 60 percent between 1997 and 2023, while new diagnoses at older ages plateaued or declined. (Read More)

(New York Times) – You’ve probably heard of extreme cases in which people treat bots as lovers, therapists or friends. But many more have them intervene in their social lives in subtler ways. On dating apps, people are leaning on A.I. to help them seem more educated or confident; one app, Hinge, reports that many younger users “vibe check” messages with A.I. before sending them. (Young men, especially, lean on it to help them initiate conversations.)

In the classroom, the domain I know best, some students are using the tools not just to reduce effort on homework but also to avoid the stress of an unscripted conversation with a professor — the possibility of making a mistake, drawing a blank or looking dumb — even when their interactions are not graded. (Read More)

(New York Times) – Every few months, he acts out more than usual and he is hospitalized. Doctors administer enough medication to briefly calm him, then label him “stable” and “not a harm to self or others” and discharge him back to the streets, where he is exposed to harsh winter nights without any support — sometimes even without shoes or a jacket.

This is not anonymous urban homelessness. It is local and relational, playing out in full view of his childhood friends, former teachers and soccer coaches. They don’t know how to help him any more than we do. (Read More)

(New York Times) – Obamacare’s open enrollment period is over, and Americans around the country are facing higher health insurance costs. But the increases have been particularly steep for one group of people.

People who earn $62,600 or less — the people whose incomes fall on the left side of this chart — get income-based subsidies to pay most of the bill.

People who earn more than $62,600 — the people on the right side — get no subsidies at all. They pay full price.

That means an increase of $1 in income for the average 60-year-old — from $62,600 to $62,601 — could mean paying $10,000 more for health insurance. (Read More)

(New York Times) – As an employee with the N.S.A., he claimed he was exposed to a direct-energy device that led to a diagnosis of Parkinson’s disease at age 45.

Michael Beck, the first of scores of federal workers to develop neurological symptoms while serving at U.S. government facilities overseas, a condition that has come to be known as Havana Syndrome and which, Mr. Beck claimed, resulted in his diagnosis of a rare form of Parkinson’s disease when he was 45, died on Saturday in Columbia, Md. He was 65.

His daughter, Regan, said that he died while shopping and that the cause had not been determined. (Read More)

(Reuters via MSN) – The Trump administration has told global vaccine group Gavi to phase out shots containing the preservative thimerosal as a condition of providing the group with funding, a U.S. official and a Gavi spokesperson told Reuters.

The request, which Reuters is the first to report, is the latest sign of efforts by the administration of President Donald Trump to influence health policy globally. (Read More)

(NBC News) – A person’s genes play a far greater role in likely lifespan than previously thought, according to a major new study published Thursday in the journal Science.

Using data from human twin studies, an international team of researchers arrived at the conclusion that the genetic contribution to how long we’re likely to live is as high as 55%.

This new finding is strikingly higher than previous estimates, which have calculated the role of genetics in lifespan could range from 6% to 33%. (Read More)

(Nature) – The external, artificial-lung system could be used to treat other people who are critically unwell and awaiting transplants.

A 33-year-old man survived for 48 hours without his lungs, after a medical team replaced the organs with an external artificial-lung system that it developed to keep him alive until he could receive a double lung transplant.

There have been cases in which people have had their lungs removed and been connected to an external device to maintain oxygen levels. But, the devices used in these cases don’t count as artificial lungs because they do not maintain blood flow across the heart, meaning it cannot function normally, says Ankit Bharat, a thoracic surgeon at Northwestern University Feinberg School of Medicine in Chicago, Illinois, who helped to develop the artificial system. (Read More)

(Wired) – For years, people from CEOs to novelists have taken tiny amounts of psychedelics to support well-being. New research shows that benefits for depression may be attributable to a placebo effect.

A Phase 2B trial of 89 adult patients conducted by Melbourne-based MindBio Therapeutics, investigating the effects of microdosing LSD in the treatment of major depressive disorder, found that the psychedelic was actually outperformed by a placebo. Across an eight-week period, symptoms were gauged using the Montgomery-Åsberg Depression Rating Scale (MADRS), a widely recognized tool for the clinical evaluation of depression. (Read More)